Compare VEON & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | TLX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United Arab Emirates | Australia |
| Employees | N/A | 1184 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.6B |
| IPO Year | 2010 | N/A |
| Metric | VEON | TLX |
|---|---|---|
| Price | $51.68 | $10.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $73.40 | $21.13 |
| AVG Volume (30 Days) | 79.2K | ★ 181.0K |
| Earning Date | 05-13-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $1.60 | N/A |
| P/E Ratio | ★ $6.15 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.60 | $6.28 |
| 52 Week High | $64.00 | $16.85 |
| Indicator | VEON | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 44.54 |
| Support Level | $51.71 | $10.06 |
| Resistance Level | $55.39 | $11.38 |
| Average True Range (ATR) | 1.54 | 0.28 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 23.44 | 13.12 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.